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PYRIDOXAL KINASE (PL KINASE): ROLE IN VITAMIN B6 METABOLISM
By Jigarkumar V. Desai, M.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Master’s of Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2010

Major Director: Dr. Martin K. Safo
Associate Professor, Department of Medicinal Chemistry

Pyridoxal kinase (PL kinase) and pyridoxine 5’-phosphate oxidase (PNP oxidase)
are the two vitamin B6 salvage enzymes involved in metabolism of the primary inactive
vitamin B6 (pyridoxal, pyridoxine and pyridoxamine) into the active cofactor form,
pyridoxal 5’-phosphate (PLP). PLP, arguably the most important vitamin, is required by
numerous vitamin B6 (PLP-dependent) enzymes as a co-factor. These enzymes serve vital
roles in the metabolism of glucose, lipids, amino acids, heme, DNA/RNA and many
neurotransmitters.
High levels of vitamin B6 are linked to neurotoxicity, due to the non-specific
interactions of PLP with non-B6 proteins. This problem is controlled, in part, by
maintaining a low in vivo concentration of free PLP (~1 μM); raising the intriguing
question of how the cell regulates, as well as, supplies sufficient PLP to meet the
requirements of B6 enzymes. Similar to PLP excess, PLP deficiency, due to mutations in
xii

PL kinase and PNP oxidase or drug-induced inhibition of their activity, has been
implicated in many pathological conditions.
The objective of this study is to elucidate the mechanisms underlying PLP
regulation by PL kinase, and its subsequent transfer to dozens of PLP-dependent enzymes.
A second objective is to gain valuable information into whether a missense mutation
(S261F) in PL kinase could affect the enzyme activity and/or structure. A third objective is
to understand how vitamin B6 metabolism by PL kinase is disrupted by the neurotoxic
compound, ginkgotoxin.
The mutant (hPL kinase S261F) was obtained using site-directed mutagenesis. It
was then expressed, purified and analyzed by circular dichroism, fluorescence
spectroscopy, enzyme kinetics and native-PAGE. Our results showed no considerable
differences between wild-type enzyme and the mutant, suggesting the mutation to be nonpathogenic.
PLP was found to inhibit PL kinase by binding to the substrate PL site in the
presence of substrate MgATP to form an abortive ternary complex (PL kinase-PLPMgATP). The physiological significance of this ternary complex was also analyzed and it
was found to be a source of PLP transfer to apo B6 enzymes.
Enzyme kinetics, affinity chromatography and fluorescence polarization techniques
were used to test our hypothesis that the reactive PLP is transferred from PL kinase to apoB6 enzymes via channeling. Channeling should provide an efficient and protected way for
PLP transfer from the kinase or oxidase to apo-B6 enzymes. Our results provide a strong
support to the channeling mechanism.
xiii

Ginkgotoxin was found to be a competitive inhibitor of PL kinase with a Ki of 18
μM. X-ray crystallographic analysis of its binding mode to PL kinase confirmed its binding
to the substrate PL site of the enzyme. A unique hydrophobic interaction between its
lipophilic side chain 4’-OCH3 and nearby Tyr127 and Val231, in addition to the conserved
PL binding interactions, was found to be responsible for its higher affinity to the enzyme.

xiv

CHAPTER 1
GENERAL INTRODUCTION

1.1 B6 vitamers: Vitamin B6 is arguably the most important vitamin. It consists of
three different 3-hydroxy-2-methyl-pyridine derivatives, including pyridoxal

(PL),

pyridoxine (PN), and pyridoxamine (PM) (Figure 1). Plants and prokaryotes synthesize these
B6 vitamers de-novo from small metabolites, but mammalian cells cannot carry out de-novo
synthesis.4,

9, 10

They are mainly dependent upon dietary intake of the vitamins. The non-

phosphorylated B6 vitamers are not biologically active and must be phosphorylated to attain
activity (Figure 1). Among the phosphorylated derivatives, only pyridoxal 5’-phosphate
(PLP), and to a lesser extent, pyridoxamine-5’phosphate (PMP) is biologically active.4-7

Figure 1: Structures of the B6 vitamers
1.2 Vitamin B6 metabolism: The bio-activation of vitamin B6 derivatives is carried out
by two key enzymes; pyridoxal kinase (PL kinase) and pyridoxine 5’-phosphate oxidase (PNP
oxidase). Together these enzymes are responsible for PLP synthesis in the salvage pathway, as
shown in Figure 3. This pathway is active in both prokaryotes and eukaryotes, while de-novo
pathway for PLP synthesis is only active in prokaryote, in which PLP is synthesized from
erythrose-4-phosphate by a series of steps, as shown in Figure 2. In the salvage pathway
1

pyridoxal kinase carry out phosphorylation of all the three forms of vitamin B6, by transferring γphosphate of ATP to 5’–OH group of B6 vitamers; while PNP oxidase is responsible for
oxidation of PNP and PMP to PLP in both the salvage and de-novo pathways (Figures 2 & 3).
PLP is recycled during protein turnover via the salvage pathway involving PLP-phosphatase, PL
kinase and PNP oxidase. Released PLP from proteins is first converted by the phosphatases to
PL. PNP and PMP in the cells are also converted to PN and PM by phosphatases. These vitamers
are then acted upon by the oxidase and kinase as described above. Pyridoxal 5’-phosphate (PLP)
is required as a co-factor by over 140 different vitamin B6 (PLP-dependent) enzymes to carry out
their biological functions. These enzymes are involved in carrying out several diverse reactions
including, but not limited to neuro-transmitter catabolism, synthesis of polyamines, methionine
metabolism, heme biosynthesis, sphingomyelin synthesis, carbohydrate metabolism, nucleic acid
synthesis and homocysteine metabolism.1-3 The metabolism of B6 vitamers can be illustrated
schematically as shown in Figures 2 and 3;

2

Figure 2: De-novo and Salvage pathways for PLP synthesis; De-novo being active only in
prokaryotes, while Salvage pathway being active in both prokaryotes and eukaryotes

Figure 3: Metabolism of B6 vitamers (Salvage pathway)

3

1.3 Pyridoxal kinase: This enzyme is responsible for phosphorylation of B6 vitamers in
the salvage pathway, in both eukaryotes and prokaryotes. It catalyzes the transfer of γ-phosphate
from ATP to the 5’-CH2OH of the B6 vitamers, as shown in Figure 4. Most organisms possess
PL kinase encoded by the gene pdxK, which is highly homologous among prokaryotes and
eukaryotes.5 In addition to the PL kinase coded by the pdxK gene, E. coli and several other
prokaryotes are also found to contain a homolog PL kinase enzyme (PL kinase 2) coded by the
gene pdxY.

4, 5, 9

PL kinase 2 shares very low sequence identity (~30%) with PL kinase.5 This

protein also functions in salvage pathway but is catalytically very less active as compared to PL
kinase, therefore its exact role in vitamin B6 metabolism is not clear.4

Figure 4: Reaction catalyzed by Pyridoxal kinase
The PL kinase enzyme follows random sequential addition of substrates.6 There are
several reports about the effects of monovalent and divalent metal cations on the activity of PL
kinase and for optimal activity, K+ and Mg2+ are required.4, 6, 7, 9
PL kinases have been purified from several organisms and for many of them crystal
structures are also known.5, 6, 9, 46 All of them show a typical ribokinase superfamily structure of
core β-sheets surrounded by α-helices (Figure 5A).6 All of them are dimers with active site in
each subunit (Figure 5B), with conserved ATP and substrate binding geometries. Human enzyme

4

is more tolerant to changes in substrate chemistries, hence more prone to binding by substratelike molecules, including many commonly used drugs.6, 26
A).

B).

Figure 5: Overall structure of hPL kinase.6 (A) The monomeric structure with bound ATP
(stick), MPD (stick), Na+ (brown sphere), and Mg2+ (magenta sphere) at the active site. α-Helices
and β-strands are colored yellow and red, respectively. The secondary structures are labeled. (B)
The dimeric structure, also with bound ATP (cyan CPK), MPD (gray CPK), Na+ (brown sphere),
and Mg2+ (magenta sphere). Monomers A and B are colored red and yellow, respectively.

5

1.4 Pyridoxine 5’-phosphate oxidase (PNP oxidase): PNP oxidase is a flavin
mononucleotide (FMN) dependent enzyme, which catalyzes oxidation of PNP and PMP to PLP,
as shown in Figure 6. It is a dimer having FMN bound to each subunit, which acts as an
immediate electron acceptor, and is regenerated by transfer of the two electrons to oxygen
forming hydrogen peroxide.12 The activity of PNP oxidase is regulated by free PLP in cellular
environment, since it acts as a product inhibitor of the enzyme activity.35-38, 40, 41

Figure 6: Reaction catalyzed by PNP oxidase
1.5 PLP dependent enzymes: The PLP, after being synthesized by PL kinase and/or
PNP oxidase, is taken up by apo B6 enzymes. It binds to a specific lysine residue through a
Schiff base linkage, also called as an internal aldimine, and activates the apo enzyme to the holo
form, as shown in Figure 7.14 These PLP-dependent enzymes carry out diverse reactions such as
racemization, decarboxylation, β and γ elimination and replacement reactions.14,

16

Physiologically, these reactions are responsible for neurotransmitter synthesis, heme
biosynthesis, one carbon unit transfer and hence nucleic acid biosynthesis, sphingomyelin
synthesis and carbohydrate metabolism.1

6

Figure 7: Activation apo PLP-dependent enzymes to holo enzymes by binding of PLP to
specific lysine residue at enzyme active site via a Schiff-base linkage
Since the determination of the first structure of a PLP-dependent enzyme, aspartate
aminotransferase (AAT), structures of several PLP-dependent enzymes have been determined
and attempts have also been made to classify these enzymes. Table 1 shows one such
classification in which the PLP-dependent enzymes were classified into five different subtypes
according to the similarity in their fold; active site and amino acid sequence.14-16
Table 1: Classification PLP-dependent enzymes with representative examples of each class 15, 16
Family

Examples of PLP-dependent enzyme

Fold type I

Aspartate amino transferase (AAT)
Serine hydroxymethyltransferase (SHMT)
Glutamate decarboxylase (GAD)

Fold type II

Serine dehydratase
Cystathionine β-synthase

Fold type III

Ornithine decarboxylase
Alanine racemase

Fold type IV
Fold type V

Branched-chain amino-acid amino transferase
Glycogen phosphorylase

7

The above classification aptly exemplifies diversity of the PLP-dependent enzymes. It
also serves to explain the physiological significance of these enzymes, as well as of PLP, which
is required as a cofactor for their activity. Any alteration in PLP level may adversely affect
several body functions due to the malfunctioning of PLP-dependent enzymes.
1.6 Deficiency of PLP: Proper functioning of the PLP-dependent enzymes and thus
optimal health are dependent upon optimal level of PLP. Pyridoxal 5’-phosphate deficiency has
been implicated in several neurological and non-neurological disorders, such as induction and
development of hormone-dependent breast and prostate cancers, convulsions, peripheral nervous
system damage, impairment of immune response, epilepsy, and autism.1, 62 Most dietary sources
contain vitamin B6, hence PLP deficiency due to dietary insufficiency is less prominent.1 Major
reasons for PLP deficiency can be attributed to malfunctioning of PL kinase and/or PNP oxidase,
which may be caused either by pathogenic mutations or by drug induced inhibition of these
enzymes’ activity.
1.6.1 PLP deficiency due to pathogenic mutations: Several neurological and nonneurological disorders have been reported due to mutations in the genes coding for PL kinase
and PNP oxidase.17, 18, 19, 63, 64 These mutations may cause impairment of enzymatic activity, low
protein expressions or disruption of regulation mechanisms which can ultimately lead to PLP
deficiency.19 Mutations in the gene coding for PNP oxidase have been implicated in neonatal
epileptic encephalopathy (NEE). These mutations resulted in 70-82% reduction in enzymatic
activity.17, 19, 20, 64 Detailed characterization of one such pathogenic mutant (R229W) has been
carried out in our lab and it was shown that the mutation resulted in decrease in cofactor (FMN),
as well as substrate (PNP or PMP) binding to PNPO with concomitant decreased in enzymatic
activity.19 Similarly, defective PL kinase has been implicated in children suffering from autism.19,
8

64

Apart from these, the mutations have also been implicated in several other neurological

disorders including Alzheimer’s disease, Parkinson’s disease, learning disabilities, attention
deficit hyperactive disorder and anxiety disorders.19 Although there is no direct evidence of
linking each mutation to the disorder but detailed analysis of each mutation may serve in
designing proper treatment for affected patient.
1.6.2 PLP deficiency due to drug induced inhibition of PL kinase activity: PL kinase
inhibiting drugs can be classified into two main classes; first, direct inhibitors of the enzyme
activity; second, molecules reacting with the B6 vitamers and thereby inhibiting the enzymes.21
First class includes commonly used drugs such as theophylline, enprofylline, roscovitine and
lamotrigine, while the second class includes drugs such as isoniazid, levodopa, cycloserine and
D-penicillamine.21, 25 Many of the neuro-toxic effects of all the above mentioned drugs can be
attributed to their inhibitory effects on PL kinase. For theophylline, it is well established that it
inhibits PL kinase, to which it shows mixed inhibition.22-24 The crystal structure of theophylline
bound to pyridoxal kinase has been deposited to the PDB by our group. Roscovitine, a drug
currently being tested as a potential anti-cancer agent, is relatively selective for its target (i.e. the
cyclin dependent kinases), but recently it has been reported to bind to pyridoxal kinase at the
pyridoxal binding site.25 The crystal structure of roscovitine and its derivatives bound to
pyridoxal kinase indicates the ability of the enzyme active site to accommodate molecules much
larger than pyridoxal.26 Recently, several groups pointed out that the toxic effects of ginkgotoxin
can be attributed to its inhibitory effects on PLP-synthesizing enzymes. Ginkgotoxin is mainly
obtained from the seeds and leaves of Ginkgo biloba. Various medications from Ginkgo biloba
are widely used in the treatment of various conditions ranging from bronchial asthma, irritable
bladder, depression, dizziness, tinnitus and several others.27-31 These medications have prominent
9

presence in traditional Chinese, Japanese and European system of medicine. In Japan, the seeds,
also called as “Gin-nan”, are used as food and their consumption has resulted in about 70 food
poisoning episodes since 1930.28, 65 Apart from G. biloba, several Albizzia species also contain
Ginkgotoxin which is responsible for a condition called “Albizziosis” (Ginkgotoxin poisoning)
in S. African cattle and sheep.66 The symptoms of the toxicity mainly include seizures,
tonic/chronic convulsions, vomiting and impaired consciousness. The symptoms were found to
be alleviated by administering PLP.65 This indicates that the toxicity can be attributed to the
inhibition of PL kinase or PNP oxidase, which leads to decrease in PLP levels. The molecular
mechanism of PLP deficiency by Ginkgotoxin is still needed to be investigated.
For all the above mentioned drugs, adverse effects may be alleviated by coadministering vitamin B6 supplements. Also, knowing the binding mode of these drugs with PL
kinase may also help in selecting other putative molecules which may bind to PL kinase to elicit
their adverse effect. These findings will be helpful in improving the pharmacological profiles of
the corresponding drugs.
1.7 PLP toxicity: Excess levels of PLP have also been implicated in sensory and
peripheral neuropathies.67 Toxicity of PLP can be attributed to the electrophilic 4’-CHO group
which can react with several cellular nucleophiles.67 Because of this property, PLP is even used
to label specific amino acids to study proteins.31 Several toxicities have been reported due to
reactivity of PLP. Excess use of vitamin B6 has been implicated in sensory and peripheral
neuropathies, parethesia, demyelination, and degeneration of sensory neurons in peripheral
nerves.67-70 PLP has been reported to bind GABAA receptors via Schiff base linkage. This
binding precipitated tonic-clonic convulsions in mice.32,

33

In a similar fashion, PLP was also

found to inhibit the activity of phenol (aryl) sulfotransferase, a major detoxification enzyme.34
10

Thus, the cell requires tight regulation of PLP concentration to reduce its non-specific
interactions and thus toxicity. Figure 8 summarizes how excess, as well as deficit levels of PLP
are undesirable, necessitating tight regulation of cellular PLP levels.

Figure 8: Effects of PLP-deficiency and toxicity
1.8 Regulation of PLP: Since excess levels of PLP in the cell is undesirable, free PLP
levels have to be low. Several reports suggest that PLP does not accumulate in any body tissue.35,
47

This raises the basic question of how the concentration of free PLP is regulated in body.

Several regulatory mechanisms have been proposed and/or identified. These include action of
PLP specific phosphatase, protein binding and feed-back inhibition of PNP oxidase. Among
these, PLP specific phosphatase is believed to play very important role.35, 39, 43 This enzyme is at
least 10 fold more active than other phosphatase and it is much more specific for PLP.39 This
enzyme is homologous among all the species examined so far and it is found to be expressed
ubiquitously in all the tissues with highest expression level in the brain.39 This enzyme is
responsible for dephosphorylation of PLP to the less reactive PL and it requires Mg2+ for its
activity (Figure 9).39, 67

Figure 9: Reaction catalyzed by PLP-phosphatase
11

The kcat/Km of 0.6 μM-1s-1 of this enzyme for PLP, as compared to 0.03 μM-1s-1 of PL
kinase for PL, explains its high catalytic activity, as well as its importance in PLP homeostasis.4,
39

In addition to the action of PLP-phosphatase, feed-back inhibition of PLP synthesizing

enzymes is also believed to play a very important role in regulating PLP levels. Previously, it has
been reported that PLP inhibits PNP oxidase at Ki of 1-25 μM.35,44 Induced MgATP substrate
inhibition of PL kinase in the presence of PLP has also been reported. Our group recently solved
the crystal structure of PLP bound at the active site of PL kinase along with the substrate
MgATP, as shown in Figure 10 – (Safo et al., unpublished results). This suggests that PLP forms
an abortive ternary complex with enzyme PL kinase and substrate MgATP. Binding of PLP at
active site clearly indicates a possibility of competitive inhibition of enzyme activity by the
product, PLP. The exact kinetic behavior of PLP inhibition for PL kinase is not known yet.

Figure 10: Crystal Structure of Human PL kinase in complex with bound MgATP and PLP
at the active site.
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1.9 Mechanism of PLP transfer: As mentioned in the preceding sections, PLP
concentration is kept very low (~ 1μM) through several regulatory mechanisms, to reduce its
toxicity.35, 47 Despite this, over 140 apo B6 enzymes manage to obtain enough PLP, which binds
to a specific lysine residue at the active site of the enzymes and converts them to the fully
functional holo form, as shown in Figure 7. The question is how they obtain PLP, despite its low
in vivo concentration. Two possible mechanisms can be proposed, as shown in Figure 11.35
According to mechanism I, synthesized PLP by PL kinase and/or PNP oxidase is first released as
free PLP in the cytosol, which is then sequestered by apo B6 enzymes. The released PLP is
susceptible to dephosphorylation by PLP phosphatase to PL and may also react non-specifically
with several other nucleophiles. The second mechanism (Mechanism II) is a channeling
mechanism where PL kinase or PNP oxidase forms a complex with an apo B6 enzyme and
transfers PLP, resulting in activation of apo B6 enzyme to the holo form, without PLP on the
kinase or oxidase being released into solvent. Substrate channeling has been previously reported
for several different enzyme systems.59,
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It offers several distinct advantages such as;

prevention of loss of intermediate by diffusion, protection of labile intermediates from solvent,
and prevention of entry of intermediates to other metabolic pathways.58,59 Previous studies have
shown that PL kinase can interact with PLP-dependent enzymes like aspartate aminotransferase,
glutamate decarboxylase, and alanine aminotransferase.35, 47 A study by the Schirch group also
showed that activation of apo B6 enzyme to the holo form in cell extract was more efficient using
PLP synthesized by PNP oxidase compared to the use of free PLP as shown in Figure 12.12 The
authors suggested that free PLP in the extract was forming non-productive aldimines with cell
components, e.g. amino acids and proteins. These served to suggest a very strong possibility of
PLP channeling.
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Figure 11: Hypothetical mechanisms for transfer of PLP from PLP synthesizing enzymes to
apo PLP-dependent enzymes
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Figure 12: Activation of apo eSHMT by PLP and apo PNP oxidase-PLP12. (I) Apo eSHMT,
20 μM, was incubated with 25 μM PLP in 20 mM potassium phosphate, pH 7.3. Aliquots (5 ml)
were removed every few minutes and assayed for eSHMT activity by observing the increase in
absorbance at 340 nm/min in a coupled enzymatic assay. (II) Apo eSHMT was incubated under
the same conditions as described above except the phosphate buffer included 0.3 g/ml of dried
E. coli cell extract that lacks any SHMT activity. (III) Apo eSHMT, 20 mM, was incubated in
the E. coli cell extract except the PLP was replaced with 25 μM PNPO-PLP
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1.10 Rationale and Specific Aim
Vitamin B6, as PLP, serves as a co-factor in over 140 enzymatic reactions and any
decrease in PLP level in the cell, either due to mutations in the genes coding for PL kinase and/or
PNP oxidase or drug induced inhibition of their activity, results in malfunctioning of PLPdependent enzymes, which leads to several neurological, as well as, non-neurological disorders.
The PLP levels, above physiological limit, have also been implicated in several neuropathies.
Thus tight regulation of PLP concentration is required in the cell. The overall objective of this
study is to elucidate the mechanisms underlying PLP metabolism and regulation, and its
subsequent transfer to dozens of PLP-dependent enzymes. Another objective is to gain valuable
information into how pathogenic mutations in PL kinase as well as inhibition of this enzyme by
compounds disrupt vitamin B6 metabolism. The study is divided into four specific aims;
1.

Determine the kinetic regulation of PLP by PL kinase and the mechanism of PLP

transfer to apo B6 enzymes
2.

Characterize protein-protein interactions between PL kinase and B6 enzymes

3.

Determine the effect of PL kinase S261F mutation on PL kinase activity and

structure
4.

Determine the effect of ginkgotoxin on PL kinase activity and structure
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CHAPTER 2
DETERMINE THE KINETIC REGULATION OF PLP BY PL KINASE AND
THE MECHANISM OF PLP TRANSFER TO APO B6 ENZYMES
2.1 Introduction: The non-specific interactions of PLP with non B6 proteins, due to high
chemical reactivity of the aldehyde group on PLP, are controlled in part by maintaining a low in
vivo concentration (~1 μM) by several regulatory mechanisms. These mechanisms include the
action of PLP phosphatase and protein binding of PLP.35, 39, 62, 81 Feed-back inhibition of PNP
oxidase activity by PLP also plays an important role.36-38 In addition, inhibition of human PL
kinase activity by the product ADP (Safo et. al. - unpublished results), and the substrate MgATP
in presence of PLP,4 have also been reported. However, unlike the PNP oxidase, there are no
detailed studies on the regulatory effect of PLP on PL kinase activity.
The low in vivo concentration of free PLP, as well as its highly reactive nature raises an
intriguing question of how the cell supplies sufficient PLP, with high specificity, to the dozens of
B6 enzymes. There are two possible mechanisms for PLP transfer to apo B6 enzymes-via
channeling of PLP from the kinase or oxidase to the apo B6 enzymes, or via release of the PLP
from the kinase and oxidase into cytosol as free PLP which then finds its way to the apo B6
enzymes.
This chapter focuses on elucidating the effects of PLP on catalytic activity of PL kinase,
as well as determining the significance of a ternary abortive complex formed between PL kinase,
MgATP and PLP (referred to as PL kinase-PLP-MgATP). We will also elucidate the mechanism
involved in the transfer of PLP from PL kinase to activate apo B6 enzyme to the holo form.
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2.2 Materials: Bacterial culture media ingredients were purchased from Fischer
Scientific (Pittsburgh, PA) and American Bioanalytical (Natick, MA). All the substrates were
purchased from Sigma (St. Louis, MO) or Fischer Scientific (Pittsburgh, PA). Sephadex G50
was purchased from Fischer Scientific (Pittsburgh, PA). DEAE sephadex, ceramic
hydroxylapatite, and CM sephadex were purchased from Sigma (St. Louis, MO). Nickel
nitriloacetic acid (NiNTA) was purchased from Qiagen (Valencia, CA). Centrifugal filter devices
were obtained from Milipore (Bedford, MA). The recombinant plasmid containing the gene
insert coding for PLP-phosphatase was obtained from the Boe group (Bergen, Norway).
2.3 Methods
2.3.1 Expression and purification of human PL kinase (hPL kinase): The human PL
kinase was purified using the procedure described previously.5,
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Briefly, competent E. coli

Rosetta (DE3) pLysS cells (Novagen) were transformed with a pET28b vector carrying the
human pdxK gene insert. Transformants were grown in 6 liters of LB-kanamycinchlroamphenicol (kanamycin 50 μg/mL and chlroamphenicol 34 μg/mL) media and after
reaching optical density of 0.8 at 600 nm, were induced with 0.5 M mM IPTG. Cells were grown
for additional 5 hours at 32ºC and harvested by centrifugation. The cell pellets were resuspended in 250 ml of 50 mM sodium phosphate buffer, pH 8.0 and rapidly ruptured by high
pressure homogenization using Avestin cell disrupter. Streptomycin sulfate was added to a final
concentration of 10 g/L to remove excess nucleic acids. After ammonium sulfate fractionation (at
30% and 60% saturation), enzyme was dialyzed in 50 mM sodium phosphate buffer, pH 8.0. The
desalted protein solution was loaded on Ni-NTA column which was equilibrated with 50 mM
monobasic sodium phosphate, pH 8.0, containing 300 mM NaCl, and 5 mM imidazole. The
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column was washed thoroughly with equilibration buffer until OD280 was less than 0.1, and
further washed several times with the same buffer, containing higher concentration of imidazole
(10-75 mM). The enzyme was eluted from the column with 50 mM monobasic sodium
phosphate buffer, pH 8.0, containing 300 mM NaCl, and 150 mM imidazole. Fractions
containing 95% purity, as judged by SDS-PAGE, were pooled and the protein solution was
concentrated by precipitation with 60% ammonium sulfate. The protein pellets were stored at 20°C for further usage.
2.3.2 Assay of PL kinase activity: The analysis of activity was carried out in 1cm
thermostated cuvette in Agilent 8454 spectrophotometer at 37°C by recording increase in
OD388 nm, which indicates PLP formation from PL in presence of MgATP, as shown in Figure
13.4 PL kinase (10-20 μM) was mixed with 1 mM MgATP in 20 mM sodium BES, pH 7 and the
reaction was started by addition of 150 μM PL. The increase in OD at 388 nm was recorded for
60 seconds in kinetic mode of the software.

Figure 13: Assaying pyridoxal kinase activity

2.3.3 Expression and purification of E. coli serine hydroxymethyltransferase
(eSHMT): The eSHMT was purified by a previously reported method, with minor
modifications.49 Briefly, the cDNA of gene glyA, coding for eSHMT, was inserted in vector pGS
29. The recombinant plasmid was transformed in E. coli K-12 cells. Transformants were grown
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in 6 L LB-ampicillin (ampicillin 100 μg/mL) media containing 25 mM potassium phosphate (pH
7.4) and 0.4% glucose, at 37°C until they left the log phase of growth, as monitored by OD600nm,
and harvested by centrifugation. The cells, after re-suspension, were lysed by homogenization at
high pressure using Avestin cell disruptor. After ammonium sulfate fractionation (50% and 75%),
protein pellet was dissolved in 20 mM potassium phosphate buffer, pH 7.2 and dialyzed
extensively against the same buffer containing 0.1 mM PLP and 1mM EDTA. The desalted
protein was loaded on DEAE-Sephadex column, which was pre-equilibrated with 20 mM
potassium phosphate buffer, pH 7.2 The column was washed thoroughly with the equilibration
buffer until OD at 280nm was below 0.2 and then the protein was eluted with linear salt gradient
of 400 mL equilibration buffer and 400 mL of 50 mM potassium phosphate buffer, pH 6.4
containing 300 mM NaCl. Spectra of each fraction were recorded using UV-Visible
spectrophotometer between 250-550nm. The fractions having value of OD280nm/OD423nm ratio
below 50 were collected and analyzed by SDS-PAGE analysis for purity. Fractions containing
pure protein were pooled together and protein was precipitated by adding ammonium sulfate to
75% saturation. The precipitate was dissolved in 20 mM sodium BES buffer, pH 7 and dialyzed
against the same buffer containing 0.1 mM PLP. The activity of desalted protein was analyzed. It
was then loaded on hydroxylapatite column, pre-equilibrated with 20 mM sodium BES, pH 7.
The column was washed thoroughly with equilibration buffer until OD at 280nm was below 0.2
The protein was eluted with linear gradient of 50 mL equilibration buffer and 50 mL of 100mM
potassium phosphate buffer, pH 7. The fractions having value of OD280nm/OD423nm ratio below 50
were collected and analyzed by SDS-PAGE analysis. Fractions of highest purity were pooled
together. The pooled fractions were finally loaded on TMAE column, from which protein of
almost 95% purity was obtained.
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2.3.4

Expression

and

purification

of

rabbit

cytosolic

serine

hydroxymethyltransferase (rcSHMT): The rcSHMT was expressed and purified by a
previously reported method.50 Briefly, the recombinant plasmid containing the gene insert coding
for rcSHMT was transformed into E. coli HMS (DE3) cells. Transformants were grown in 6 L
LB-ampicillin (ampicillin, 100 μg/mL) media containing 0.5% glucose, and buffered with 50
mM phosphate (pH 7.3), prepared from dibasic potassium phosphate and monobasic sodium
phosphate. Cells were grown at 37°C till OD600nm reached 1.2, induced with 0.5 mM IPTG,
grown for additional 7 hours and then harvested by centrifugation. Cell pellets were resuspended in 20 mM potassium phosphate, pH 7.3 containing 0.1 mM PLP, 5 mM 2mercaptoethanol and 0.1 mM EDTA and ruptured by high pressure homogenization using
Avestin cell disruptor. The protein was then precipitated by adding ammonium sulfate to 55%
saturation. The precipitate was dissolved in 20 mM potassium phosphate buffer, pH 6.8 and
dialyzed extensively against the same buffer containing 0.1 mM PLP and 1mM EDTA. This
desalted protein was loaded on CM-Sephadex column, pre-equilibrated with 20 mM potassium
phosphate buffer, pH 6.8. The column was washed thoroughly with the equilibration buffer until
OD at 280nm was below 0.2 Protein was eluted with linear gradient containing 600 mL
equilibration buffer and 600 mL of 300 mM potassium phosphate buffer, pH 7, containing 5 mM
2-mercaptoethanol and 0.1 mM EDTA. The spectra of fractions were recorded between 250-500
nm using UV-visible spectrophotometer. Fractions having OD280nm/OD423nm ratio less than 50
were collected and analyzed by SDS-PAGE. Fractions containing pure protein were pooled
together and the protein was precipitated by adding ammonium sulfate to 60% saturation. The
precipitate was dissolved in 20 mM potassium phosphate buffer, pH 7.3 containing 5 mM 2-
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mercaptoethanol, 0.1 mM EDTA and 0.1 mM PLP. It was dialyzed against the same buffer and
this desalted protein was analyzed for activity and stored at -20°C for further usage.
2.3.5 Activity analysis of Serine hydroxymethyltransferase: Activity analysis of
SHMT was carried out by a coupled reactions assay.49, 50, 56 In the assay, allothreonine was used
as a substrate for SHMT and the rate of formation of acetaldehyde was measured by reducing it
to ethanol by NADH and alcohol dehydrogenase. NADH absorbs at 340nm, but when it gets
oxidized to NAD+ during reduction of produced acetaldehyde to ethanol, gradual decrease in
OD340nm is observed. Therefore the activity of SHMT was monitored by recording change in
OD340nm in 1 cm thermostated cuvette at 30°C using Agilent 8454 spectrophotometer. About 10
μg SHMT was mixed with 90 μg alcohol dehydrogenase and 180 μg NADH in 50 mM sodium
BES buffer, pH 7.3 The reaction was started by addition of 10 μM allothreonine and decrease in
OD at 340 nm was followed for 60 seconds.
2.3.6 Expression and purification of human PLP-phosphatase: The human PLPphosphatase was purified by a previously reported procedure with minor modifications.39 The
recombinant plasmid containing the gene insert, coding for PLP-phosphatase, was transformed to
E. coli HMS (DE3) pLys cells. The transformants were grown in 6 L LB-ampicillin media
(ampicillin 100μg/mL). Cells were grown at 37°C until OD600nm reached 0.6, induced with 50
μM β-isopropylthiogalactopyranoside (IPTG), grown for additional 24 hours at 18°C and then
harvested by centrifugation. The cell pellets, after re-suspension, were lysed by high-pressure
homogenization using Avestin cell disruptor. Streptomycin sulfate was added to the cell lysate at
final concentration of 10g/L to remove excess nucleic acids. After centrifugation, the lysate was
loaded on NiNTA column, pre-equilibrated with 50 mM monobasic sodium phosphate, pH 8.0,
containing 300 mM NaCl, and 5 mM imidazole. The column was washed thoroughly with
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equilibration buffer until the OD280 was less than 0.1, and further washed several times with the
same buffer, containing higher concentration of imidazole (10-75 mM). The enzyme was eluted
from the column with 50 mM monobasic sodium phosphate buffer, pH 8.0, containing 300 mM
NaCl, and 150 mM imidazole. Fractions containing 95% purity, as judged by SDS-PAGE, were
pooled and the protein solution was concentrated by precipitation with 60% ammonium sulfate.
The precipitate was dissolved in 0 mM sodium BES buffer, pH 7 containing 4 mM MgCl 2 and
dialyzed against the same buffer. It was stored at -20°C for further usage.
2.3.7 Activity analysis of PLP-phosphatase: The analysis of PLP-phosphatase activity
was carried out in 1cm thermostated cuvette in Agilent 8454 spectrophotometer at 37°C by
recording a decrease in OD388 nm, which indicates dephosphorylation of PLP to PL, as shown in
Figure 14.39, 43 PLP-phosphatase was taken in 20 mM sodium BES buffer, pH 7 containing 4 mM
MgCl2. The reaction was started by addition of the substrate PLP at concentration of 100 μM and
decrease in OD at 388 nm was recorded for 60 seconds.

Figure 14: Assay of PLP-phosphatase activity
2.3.8 Preparation of ePL kinase-PLP-MgATP ternary abortive complex: PL kinase
(300 μM) was mixed with its substrates, pyridoxal (PL, 400 μM) and MgATP (1 mM) in 20 mM
sodium BES, pH 7 and incubated at 37°C for 1 hour. This reaction mixture was passed through
Sephadex G50 column (0.6 x 45 cms), pre-equilibrated with 20 mM sodium BES, pH 7
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containing 1 mM MgATP. About 400 μL fractions were collected and analyzed for eluted
protein and PLP, by recording optical density at 280nm and 388nm respectively. Fractions
containing high concentration of protein were pooled together and stored in 500 μL aliquots at
-20°C for further use.
2.3.9 Preparation of apo serine hydroxymethyltransferase: Apo enzyme was prepared
according to the method previously reported.49 Briefly, holo SHMT (eSHMT or rcSHMT, 500
μL) was mixed with EDTA (1 μM), dithiothreitol (DTT, 1 μM), D-alanine (200 μM) and
ammonium sulfate (200 μM) in 50 mM potassium phosphate buffer, pH 7. The reaction mixture
was incubated at 37°C with shaking at 150-180 rpm until the yellow color disappeared. It was
dialyzed extensively against 50 mM potassium phosphate, pH 7.4 containing 0.5 mM EDTA and
1mM DTT. The apo enzyme was quantified by measuring protein absorbance at 280 nm. It was
then stored in 500 μL aliquots, containing 10% glycerol, at -70°C.
2.3.10 Determination of stoichiometry of PLP binding to ePL kinase-PLP-MgATP
complex: The stoichiometry of PLP binding was analyzed by two different methods. In the first
method, ePL kinase-PLP-MgATP (100 μL, 10-15 μM) was diluted to 900 μL and OD280nm was
measured to quantify protein. To this, NaOH solution was added to a final concentration of 0.1 N
and OD388nm was recorded. The released PLP was quantified using molar extinction co-efficient
of 6600 M-1cm-1. In the second method, PLP was used to activate apo SHMT to holo SHMT.
This holo SHMT ultimately forms a ternary quinonoid complex with glycine and
tetrahydrofolate (THF) having absorption maximum at OD491nm. First, known concentrations of
PLP (5-25 μM) were added to the reaction mixture of apo SHMT (20 μM), glycine (50 mM) and
THF (100 μM). Formation of the quinonoid complex was followed for 15 minutes and
∆OD491nm/15min values obtained for different concentrations of added PLP were used to plot a
24

standard curve of ∆OD491nm versus PLP concentration. From the ePL kinase-PLP-MgATP
complex, PLP was first released by adding it to 0.1 N NaOH solution. The complex was added to
a final concentration of 10-15 μM. This mixture was then added to 350 μL of 100 mM sodium
BES buffer, pH 6.5 to bring pH at 6.5. To this mixture; apo SHMT, glycine and THF were added
to final concentrations of 20 μM, 50 mM and 100 μM respectively. The reaction was followed
for 15 minutes and the ∆OD491nm/15min value was recorded, which was further used to
extrapolate the amount of PLP released from the standard curve. This amount of PLP was
compared with the protein concentration to find out the stoichiometry of PLP binding.
2.3.11 Kinetic analysis of inhibition of PLP on PL kinase activity: The assay for PL
kinase activity was carried out in 20 mM sodium BES buffer, pH 7 containing 2 mM MgCl2 at
37°C using Agilent 8454 spectrophotometer as described previously under section 2.3.2.
Substrates PL and MgATP were used at concentrations of 150 μM and 1 mM respectively, while
PL kinase was used at concentration of 10 μM. Concentration of PLP was varied between
1-500 μM to analyze its effects on PL kinase activity. Initial velocity data were recorded and
“% enzyme activity” was calculated. It was plotted against PLP concentration and fitted in
Sigmaplot-11. An approximate Ki value for PLP inhibition was determined by using ChengPrusoff equation42 (Equation 1), in which PL was considered as a substrate to which PLP acted
as a competitive inhibitor.

where, [S] = concentration of PL, 150 μM
Km = 30 μM for PL
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2.3.12 Test of compartmentation or channeling of PLP from ePL kinase to apo
SHMT: The transfer of PLP from PL kinase to apo SHMT was followed by a coupled assay, in
which the PLP synthesized by PL kinase was used to convert apo SHMT to holo form. This holo
SHMT formed a ternary quinonoid complex absorbing at 491 nm. The enzymes
ePL kinase (20 μM), apo eSHMT (20 μM) and PLP-phosphatase (3 μM) were mixed together
with glycine (50 mM), tetrahydrofolate (100 μM) and MgATP (1 mM) in 20 mM sodium BES
buffer pH 7. The reaction was started by addition of PL (20 μM) and increase in OD491nm was
followed for 15 minutes.
Controls were run in parallel. First control contained apo SHMT and PL kinase with all
the substrates, but PLP-phosphatase was omitted. Second control contained free PLP, and
apo SHMT with its substrates, but PL kinase and its substrates MgATP and PL were omitted. In
this case, the reaction was started by addition of PLP to the enzyme mixture. Third control
contained free PLP and apo SHMT with its substrates, but PL kinase, its substrates and PLPphosphatase were omitted.
Similar experiments were run to analyze the transfer of tightly bound PLP from ePL
kinase-PLP-MgATP to apo SHMT. For this, the enzymes apo SHMT (20 μM) and PLPphosphatase (3 μM) were mixed with glycine (50 mM) and tetrahydrofolate (100 μM) in 20 mM
sodium BES buffer, pH 7 containing 1 mM MgATP. Reaction was started by addition of tightly
bound PLP (20 μM) in form of ePL kinase-PLP-MgATP complex and OD491nm was followed for
15 minutes. Activation of apo SHMT by free PLP, in presence and in absence of PLPphosphatase, was also followed as control. In another control, activation of apo SHMT was
followed by addition of tightly bound PLP in form of ePL kinase-PLP-MgATP without the
addition of PLP-phosphatase.
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Figure 15: Scheme for following transfer of PLP from PL kinase to apo SHMT
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2.4 Results and Discussion:
2.4.1 Purity of the enzymes: All the enzymes were >90% pure as judged by SDS-PAGE
analysis. Figure 16 shows the pictures of gels after the final column in the purification of each
enzyme;
A)

B)

C)

Figure 16: SDS-PAGE analysis of the fractions eluted out from the final column for
purification of A) hPL kinase, B) eSHMT C) rcSHMT
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2.4.2 Binding of PLP to PL kinase as a ternary complex with substrate MgATP
(PL kinase-PLP-MgATP): PNP oxidase purified from brain and liver tissues was found to be
inhibited by the product PLP at Ki ranging from 1-25 μM.37, 38, 41, 44 Choi and Churchich reported
that PLP in 10-fold excess inhibits sheep brain PNP oxidase significantly, and the inhibition was
due to binding of PLP via aldimine linkage to a specific lysyl residue on protein.36 Similarly, E.
coli PNP oxidase was also found to be inhibited by PLP.40 The characterization of PLP binding
to E. coli PNP oxidase has also been carried out and PLP was found to bind tightly at a noncatalytic site of the enzyme.12 This tightly bound PLP was found to be a very good source to
activate apo SHMT in the cell extract, as compared to free PLP.12 These observations suggest
that PLP, in addition to exerting product inhibition on PNP oxidase, may bind to the enzyme at
non-catalytic site, which may serve as a control mechanism for PLP regulation. PLP binding to
human PL kinase has also been reported and the crystal structure of human PL kinase complexed
to PLP and MgATP has been deposited to Protein Data Bank [PDB id 3KEU]. This crystal
structure of PL kinase-PLP-MgATP shows PLP to bind at the active site of the enzyme at the PL
site. In PL kinase structures, the 5’-OH group of the substrate PL is situated 6-7 Å away from the
γ-phosphate of ATP, which provides room for co-existence of the 5’-phosphate of the product
PLP and the substrate ATP together. The bound PLP remains anchored to the active site with the
help of numerous interactions with amino acid side-chains and an additional Mg2+, as shown in
Figure 10. The crystal structure of PL kinase-PLP-MgATP gave an important insight into the
binding mode of PLP. We have conducted studies to further characterize this ternary complex
and also elucidate its possible inhibitory effect on PL kinase activity. The ePL kinase-PLPMgATP complex was prepared by incubating the enzyme ePL kinase with substrates PL and
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MgATP for an hour. The reaction mixture was then loaded on Sephadex G50 column. The
elution profile is shown in Figure 17.
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Figure 17: Elution profile of ePL kinase incubated with PL and MgATP after passing
through Sephadex G50 (0.6 x 45 cms).
The elution profile shows peaks of protein (280 nm) and PLP (388 nm). The
coincident rise of 388nm peak along with the protein peak clearly indicates the binding of PLP to
PL kinase which absorbs at 388 nm. Apart from this, free PLP was separated effectively as seen
from the elution profile. Most interestingly, and also observed previously for the tightly bound
PLP on PNP oxidase, the bound PLP on PL kinase could not be separated from the protein by
dialysis or even after passing it second time through the same column. This indicates the fact that
PLP remains tightly bound to PL kinase.
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2.4.3 Determination of stoichiometry of PLP binding: The stoichiometric binding of
PLP to PL kinase was analyzed by two different methods. In each of these methods, bound PLP
was first released by adding 0.1 N NaOH, which served to denature the protein and thus the
release of bound PLP. In the first method, the amount of PLP released was determined by
recording OD388nm and using molar absorption co-efficient of 6600 M-1cm-1 for PLP.12 Figure
18A shows the spectra of PLP, before and after the addition of 0.1N NaOH. In the second
method, the released PLP, after neutralizing the solution, was used to activate apo SHMT which
subsequently formed ternary quinonoid complex with glycine and tetrahydrofolate (THF),
absorbing strongly at 491nm. It has molar extinction co-efficient of 20000 M-1cm-1.

12, 52, 53

A

standard curve for formation of the quinonoid complex was plotted against the concentration of
PLP used. The PLP released from ePL kinase-PLP-MgATP was quantified from this standard
plot and compared to the protein concentration to determine the stoichiometry. Figure 18B shows
the standard plot of ∆OD491nm versus different PLP concentrations, from which PLP released
from PL kinase-PLP-MgATP complex was quantified. Table 2 summarizes the results obtained
by both methods and it indicates that one molecule of PLP binds to each subunit of PL kinase in
1:1 fashion.
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Figure 18: Determination of stoichiometry of PLP binding to ePL kinase-PLP-MgATP
ternary abortive complex; A) Stoichiometry determination by OD388nm method; blue curve
shows spectra of the complex before addition of 0.1 N NaOH, while red curve is spectra of the
complex after adding 0.1N NaOH, B) Stoichiometry determination using OD491nm method

Table 2: Determination of stoichiometry of PLP binding to ePL kinase-PLP-MgATP complex
OD388nm method OD491nm method
Stoichiometry (Protein:PLP) 1.01
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1.07

2.4.4 Inhibition of PL kinase activity by product PLP: The effect of PLP on the
catalytic activity of PL kinase was analyzed spectrophotometrically. Figure 19 shows the profile
for PLP inhibition of PL kinase activity. The IC50 and Ki for this inhibition by PLP are indicated
in Table 3
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Figure 19: Inhibition of catalytic activity of PL kinase by product PLP; 10 μM PL kinase
was checked for activity by converting 150 μM of PL to PLP by the transfer of γ-phosphate from
MgATP (1 mM) in presence of PLP (1-500 μM)

Table 3: Kinetic parameters for inhibition of PL kinase activity by PLP
IC50
Ki

135.9 ± 0.6 μM
22.7 ± 0.1 μM
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The obtained Ki for PLP inhibition of PL kinase activity is comparable to Ki of 23 μM for
PNP oxidase inhibition, reported by Churchich et. al.44 This suggests that PLP may also be
serving as a control factor in PL kinase activity, which acts in concert with other regulatory
mechanisms to prevent the accumulation of highly reactive PLP in cellular environment.
The obtained Ki is still higher than the average concentration of free PLP found in
cellular environment, but an explanation can be given for this. There are several reports of
formation of protein-protein complexes between PL kinase and PNP oxidase, as well as, the
complexes

between

PL

kinase

and

other

PLP-dependent

enzymes

aminotransferase, alanine aminotransferase and glutamate decarboxylase.35,

like

44, 47

aspartate

This can be

generalized for all the other PLP-dependent enzymes also, as described in following chapters.
The formation of protein aggregates like these prevent the diffusion of PLP, which increases the
local concentration of PLP to several-fold as compared to the cellular PLP levels. Keeping these
facts in mind, it can be proposed that physiologically, PLP may self-regulate its intra-cellular
levels by inhibition of the salvage enzymes, PL kinase and PNP oxidase.
2.4.5 Transfer of PLP from PL kinase to apo SHMT: We studied activation of apo B6
enzyme using PLP produced during steady state catalytic activity of PL kinase from the
substrates PL and MgATP. In a previous study Churchich et al.35 showed that PL kinase and
AAT interacted together prior to PLP transfer. They checked the possibility of PLP channeling
by including a trapping agent (alkaline phosphates), and the results showed that the phosphatase
did not have any effect on the rate of transfer, suggesting a possibility of channeling. Alkaline
phosphatase, used in their studies, is relatively non-specific and has broad substrate specificity.39
We conducted similar experiments with apo SHMT, and also used PLP-phosphatase instead of
alkaline phosphatase as a trapping agent.
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We analyzed the transfer of PLP by mixing ePL kinase, apo eSHMT and PLPphosphatase together with MgATP, glycine and THF. The assay scheme is shown in Figure 15.
The reaction was started by adding PL, which was converted to PLP by PL kinase and then
incorporated into apo eSHMT to activate it. Control in the absence of PLP-phosphatase was also
run. Another control using free PLP in the presence and absence of PLP-phosphatase were also
conducted. Figure 20 shows the result of this experiment;
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Figure 20: Test of compartmentation or channeling of PLP from ePL kinase to apo
eSHMT; activation of apo SHMT by free PLP in absence (blue curve), and in presence of PLPphosphatase (red curve). Activation of apo SHMT by PLP produced during steady state catalytic
activity of ePL Kinase, in absence (purple curve), and in presence of PLP-phosphatase (Green
curve)

35

From Figure 20, it is evident that PLP, after being synthesized by ePL kinase was
efficiently transferred to apo eSHMT despite the presence of PLP-phosphatase (green curve),
although there seems to be some slight effect by the phosphatase. Nevertheless, when free PLP
was used to activate apo eSHMT, no activation was observed (red curve). In absence of PLPphosphatase, activation either by free PLP (blue curve) or by PLP synthesized by ePL kinase in
the reaction mixture is almost similar (purple curve). This trapping experiment, although does
not conclusively prove channeling, but definitely proves that free PLP was not involved in the
transfer. For channeling to occur; both proteins, ePL kinase and eSHMT, should associate to
form a protein-protein complex. The study to characterize this complex formation is discussed in
chapter 3.
2.4.6 Transfer of tightly bound PLP on ePL kinase (ePL kinase-PLP-MgATP
complex) to apo SHMT: We have shown above that PLP binds tightly at the active-site of PL
kinase. The PLP remains bound even after dialysis or even passing it through the sizing column.
To determine if the tightly bound PLP can be transferred to apo B6 enzyme and the mode of
transfer, we followed the activation of both E. coli and rabbit apo SHMT with E. coli PL kinasePLP-MgATP complex in the presence and absence of PLP-phosphatase. Controls were run by
following activation of apo eSHMT and rcSHMT with free PLP, in absence and presence of
PLP-phosphatase. Figures 21 and 22 shows the result of the experiment;
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Figure 21: Activation of apo eSHMT by PLP (free and tightly bound); activation of apo
eSHMT by free PLP, in absence (blue curve) and in presence of PLP-phosphatase (purple curve).
Activation of apo enzyme by tightly bound PLP on ePL kinase-PLP-MgATP complex in
presence (red line) and in absence of PLP-phosphatase (green curve)
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Figure 22: Activation of apo rcSHMT by PLP (free and tightly bound); Activation of apo
rcSHMT by tightly bound PLP from ePL kinase-PLP-MgATP in absence (blue curve) and in
presence of PLP- phosphatase (green curve). Activation of apo rcSHMT by free PLP in absence
(red curve) and in presence of PLP- phosphatase (purple curve)
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The results, as shown in Figure 21, suggest that the tightly bound PLP, which did not
separate from ePL kinase-PLP-MgATP complex by dialysis and passage through sizing column,
was easily transferred to apo eSHMT to activate the enzyme (red curve). This transfer was found
to be almost not affected by action of PLP-phosphatase (green curve), while free PLP was
completely inhibited from activating the apo B6 enzyme in the presence of the phosphates
(purple

curve).

We

observed

similar

results

when

rabbit

cytosolic

serine

hydroxymethyltransferase (rcSHMT) was used instead of eSHMT (Figure 22). This study shows
that the ternary complex may be a source of PLP for activation of apo B6 enzyme, and also the
result gives additional support to the channeling mechanism. The results were also consistent
with the observation by Yang and Schirch12 that PNP oxidase-PLP is a better source of PLP for
apo SHMT activation as compared to free PLP in cell extract.
Although the concentrations of free PLP and PLP on PL kinase-PLP-MgATP are the
same, the rate of activation by free PLP is about twice that of the complex. This is in contrast to
the transfer study using steady state production of PLP. At present we do not have any
explanation, but it could be that PL kinase-PLP-MgATP forms a non-dissociating complex with
B6 enzymes and, which may hinder PLP channeling to all available sites on B6 enzymes. In
effect there is only a half-site transfer. Consistently, if free PLP is added to this complex after
700 sec (see Fig. 21 & 22), we observe fully activated SHMT.
2.4.7 Transfer of tightly bound PLP on ePL kinase (ePL kinase-PLP-MgATP
complex) to apo SHMT in absence of MgATP: We have shown that MgATP is important in
forming the ternary PL kinase-PLP-MgATP complex. The X-ray structure shows intimate
interaction between the phosphate of the ATP and phosphate of the PLP mediated by Mg2+ ion.
The above transfer study with ePL kinase-PLP-MgATP involves the use of additional MgATP (1
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mM) in the reaction buffer to keep the enzyme in the abortive form. To test whether we will
observe similar apo B6 activation profile without extra MgATP, we repeated the above
experiment without extra MgATP. The result is shown in Figure 23, and it indicates that in the
presence of PLP-phosphatase the activation of apo eSHMT was found to be lower (green curve),
as compared to the control in which PLP-phosphatase was omitted (red curve). This is in contrast
to the previous experiment with extra MgATP that showed presence and absence of phosphatase
resulted in similar activation. This suggests the importance of Mg2+ in stabilizing the binding of
both ATP and PLP at the active site.
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Figure 23: Activation of apo eSHMT by PLP in absence of 1mM MgATP; Activation of apo
eSHMT by tightly bound PLP from ePL kinase-PLP-MgATP complex in absence (red line), and
in presence of PLP-phosphatase (green curve). Activation of apo eSHMT by free PLP in absence
(blue line), and in presence of PLP-phosphatase (purple line)
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2.5 Conclusion: Cellular level of free PLP is regulated by combination of different
mechanisms including activity of PLP-phosphatase and feed-back inhibition of PNP oxidase.
This study also suggests feedback inhibition of PL kinase as another possible mechanism of PLP
regulation. PLP inhibits PL kinase by binding to the active site and forming a non-productive
ternary complex PL kinase-PLP-MgATP at Ki of 22.6 μM. Spectrophotometric and structural
data showed that one molecule of PLP binds at the active site of the enzyme at each subunit. It
remains tightly bound to the enzyme even after dialysis or after passing through a sizing column.
The transfer studies also suggest strong possibility of channeling of PLP from PL kinase to PLPdependent enzyme.
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CHAPTER 3
CHARACTERIZE PROTEIN-PROTEIN INTERACTIONS BETWEEN PL KINASE
AND B6 ENZYMES

3.1 Introduction:
The experiments described in previous chapters suggest channeling or compartmentation
to be a probable mechanism for PLP transfer from PL kinase to PLP-dependent enzymes.
Nevertheless, conclusive proof for channeling mechanism requires that a physical complex forms
between the kinase and B6 enzymes. Association of proteins into supermolecules for transfer of
substrates has been recognized for several years. Several biophysical and molecular biology
methods are available to detect and quantify protein-protein interactions. These include but not
limited to affinity chromatography, affinity blotting, immunoblotting, co-immunoprecipitation,
fluorescence polarization (FP), and Surface Plasmon Resonance (SPR).57 In our studies we used
affinity chromatography and FP to determine whether PL kinase makes specific interaction with
various B6 enzymes, a pre-requisite for channeling mechanism.
Affinity chromatography, which provides qualitative measure of the interaction, employs
a very simple approach to detect protein-protein interactions. It involves attachment of one of the
interacting partner on solid support, from which non-specific proteins are readily washed off by
buffer containing low salt concentration. The attachment can be done by using one of several
approaches, such as affinity tagging, epitope tagging or employing fusion proteins. After
immobilizing one of the interacting partners on solid support, the other partner or cell lysate is
added on it. This added protein or any protein in the cell lysate, if interacts with the immobilized
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protein, will also be immobilized on the solid support, while other non-specific proteins get
washed off. The interacted proteins are co-eluted and analyzed to confirm the interaction.
Fluorescence polarization is a very sensitive technique for the quantification of proteinprotein or protein-ligand interactions.57, 60 The phenomenon of fluorescence polarization depends
upon the rotational movement of fluorescent molecule. Any fluorescent molecule, having an
absorption dipole parallel to the plane polarized light become excited by plane polarized light at
its excitation wavelength. It remains in the excited state for certain time (termed fluorescent lifetime, and ranges between one to ten nanoseconds) and return to ground-state while emitting
light. During fluorescent life time, the excited molecule is prone to rotational movement, which
decreases the chances of emitting the light parallel to the absorption dipole and thus results in
relative depolarization of fluorescence intensity. The rotational movement, in turn, depends upon
the molecular mass of the fluorescent molecule. Increase in molecular mass results in increase in
polarization due to decrease in rotational movement during fluorescent life-time. This property
makes this technique very useful in quantifying the protein-protein interactions, in which one of
the interacting partners is fluorescently tagged. The availability of different fluorescent dyes,
with fluorescence life-times ranging from one to ten nanoseconds, makes fluorescence
polarization a very sensitive technique for quantifying protein-protein interactions for proteins
between ten to hundreds of kilodaltons.60
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3.2 Materials: Nickel nitriloaceticacid (NiNTA) slurry was purchased from QIAGEN
(Valencia, CA). Fluorescein-5-maleimide was purchased from Invitrogen (Eugene, OR). The
Corning 96-well plates (model 3792) were purchased from Sigma Aldrich (St. Louis, MO).
Glycogen phosphorylase b was purchased from Sigma Aldrich (St. Louis , MO). All the proteins
were purified as described previously. Centrifugal filter devices were obtained from Milipore
(Bedford, MA).
3.3 Methods
3.3.1 Preparation of enzyme solutions: Purity of all the proteins was judged by SDS
PAGE. All the proteins were concentrated using Centricon-YM 30 filter devices (MWCO 30
kDa) and dialyzed against 20 mM Sodium BES, pH 7 for use in affinity chromatography
experiment, while for fluorescence polarization, they were dialyzed against 50 mM HEPES
buffer, pH 7.55 containing 150 mM KCl and 0.01% Triton. The proteins were quantified by
recording OD280nm using their extinction co-efficient as previously reported.4, 55, 73
3.3.2 Activity analyses of purified enzymes: All the purified enzymes were analyzed for
their activity as per the procedures described in previous chapter.
3.3.3

Characterization

of

protein-protein

interactions

using

affinity

chromatography: The two proteins were mixed in 1:1 stoichiometry. 1 mg of protein mixture
was taken and diluted to 100 μL with 20 mM sodium BES buffer, pH 7. This protein mixture
was loaded on NiNTA column, pre-equilibrated with 50 mM monobasic sodium phosphate, pH 8
containing 300 mM NaCl and 5 mM imidazole. The bed volume of column was 500 μL. After
loading the mixture, the column was washed thoroughly with the equilibration buffer (washing
buffer). Fractions of 400 μL were collected and analyzed for protein content by recording
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OD280nm. The column was washed till no protein came out, as observed from OD280nm. After
washing, bound protein was eluted by 50 mM monobasic sodium phosphate, pH 8 containing
250 mM imidazole and 300 mM NaCl (elution buffer). Protein elution was monitored by
recording OD280nm. Control experiments were also run, in which individual proteins, i.e. hPL
kinase and rcSHMT were loaded on NiNTA column. Fractions for washing and elution were
collected in similar fashion. Finally, the fractions for washing and elution for hPL kinase,
rcSHMT and hPL kinase + rcSHMT were analyzed by SDS-PAGE.
3.3.4 Preparation of labeled PL kinase with Fluorescein-5-maleimide: For
quantification of the protein-protein interactions, we used fluorescence polarization technique,
and this section describes the tagging of PL kinase with fluorescein-5-maleimide for this study.
Fluorescein-5-maleimide tags the protein via reacting with the –SH present on proteins. For
tagging PL kinase, fluorescein-5-maleimide (1 mM) was mixed with 50 μM PL kinase in 1 mL
of 50 mM sodium HEPES buffer, pH 7.55 containing 150 mM KCl and 0.01% Triton. The
reaction was allowed to proceed overnight at 4°C in the dark. The reaction mixture was then
centrifuged to remove any precipitate. The supernatant was dialyzed extensively against the
same buffer in dark. The degree of labelling was determined by using equation 2. Catalytic
activity of the protein was assessed before and after labelling by the assay described in chapter 2,
section 2.2.3, to determine if labelling interferes with the activity of ePL kinase.

Amax is A495 and ε’ is the molar extinction coefficient of FMI, which is 68,000 M-1 cm-1.
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3.3.5 Quantification of protein-protein interactions using fluorescence polarization
(FP): Corning 96-well plates (model 3792) were used to carry out the FP measurements to
quantify the interactions between ePL kinase and the following B6 enzymes, E. coli L-threonine
aldolase

(eL-TA),

E.

hydroxymethyltransferase

coli

aspartate

(eSHMT),

aminotransferase

rabbit

cytosolic

(eAAT),

serine

E.

coli

serine

hydroxymethyltransferase

(rcSHMT) and glycogen phosphorylase b (GlyPb) from rabbit muscle. The tagged PL kinase (1
μM) was titrated with increasing concentrations of the B6 enzymes mentioned above. The
concentrations of PLP-dependent enzymes were varied from 1μM to 50 μM. Polarization
measurements were conducted using Tecan Polarion polarimeter. The excitation wavelength and
emission wavelengths were set at 495 nm and 535 nm respectively. The polarization values (in
mP) were directly read from Microsoft Excel spreadsheet interfaced with the polarimeter. These
obtained polarization values were plotted against concentrations of PLP-dependent enzymes. The
dissociation constants for the protein-protein complexes were obtained by fitting the curves to
equation 3 using Sigmaplot 11;

Where, Pobs is the observed polarization value, P0 is the polarization value when no PLPdependent enzyme was added, Pmax is the maximum polarization value obtained upon saturation
of the polarization curve , Kd is the dissociation constant for the protein-protein complex and [E]
is the concentration of PLP-dependent enzymes.
The above equation was derived from the equation 461 by assuming the equilibrium;
FMI-PLK + E

FMI-PLK -E; where FMI-PLK is the tagged PL kinase with FMI

(fluorescein-5-maleimide) and E is the PLP-dependent enzyme.
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where, Pobs is the observed polarization values, PFMI-PLK is polarization intensity of
tagged PL kinase, PFMI-PLK-E is the polarization values of the complex of tagged PL kinase and
PLP- dependent enzyme, when all the PL kinase is in the complexed form. [FMI-PLK] and
[FMI-PLK-E] are the concentrations of uncomplexed and complexed tagged-PL kinase
respectively.
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3.4 Results and Discussion:
3.4.1 Affinity chromatography for detection of protein-protein interactions: In our
study, human PL kinase, with 6x-His tag on the N-terminal, provided a very easy way to
immobilize it on NiNTA column. In this experiment, rcSHMT was not His-tagged, nevertheless
if interaction occurs between hPL kinase and rcSHMT, it should result in immobilization of
SHMT along with the PL kinase. The possible interaction between hPL kinase and rcSHMT was
analyzed by loading 1:1 stoichiometric mixture of both enzymes on NiNTA column. Figure 24
shows the result of SDS-PAGE analysis of fractions obtained after washing (5 mM-30 mM) and
elution (150 mM-250 mM) of NiNTA column loaded with hPL kinase alone (control), rcSHMT
alone (control) and 1:1 stoichiometric mixture of hPL kinase and rcSHMT on the NiNTA
column. Table 4 describes the results of the experiment.

Figure 24: SDS-PAGE analysis of affinity chromatography eluates
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Table 4: SDS-PAGE analysis of fractions eluted out after affinity chromatography analysis to
detect interactions between hPL kinase and rcSHMT
Lane
1
2
3
4
5
6

Fraction

Result

Column loaded with hPL
kinase alone

Washing

No protein came out

Elution

Protein eluted out

Column loaded with rcSHMT
alone

Washing

rcSHMT got washed off from column

Elution

No protein was detected

Column loaded with 1:1
mixture of hPL kinase and
rcSHMT

Washing

Some unbound rcSHMT got washed off

Elution

hPL kinase and rcSHMT got co-eluted

7

Protein marker

-

From Figure 24 (lane 1 and lane 2), it can be seen that hPL kinase was successfully
immobilized on NiNTA. On the other hand, rcSHMT did not show any non-specific binding to
the NiNTA matrix, as the rcSHMT, loaded alone on the column, was found to be completely
washed off the column with the washing buffer (lanes 3 and 4). When both the proteins, i.e. hPL
kinase and rcSHMT were loaded together on column, it was found out that some of the rcSHMT
got washed off, while the major fraction of rcSHMT, which remained bound to hPL kinase, was
co-eluted along with hPL kinase. Similar experiment was conducted with lysozyme as a control,
in place of rcSHMT. The result (not displayed here) showed no interaction between hPL kinase
and lysozyme. This clearly suggests that PL kinase and SHMT interacts specifically with each
other to form a complex. This further serves to support the idea of PLP channeling. The next step
is the quantification of this protein-protein interaction, which we did by fluorescence
polarization.
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3.4.2: Fluorescence polarization (FP) to quantify protein-protein interactions: Our
previous study using affinity chromatography showed that hPL kinase forms specific interaction
with rcSHMT. Following the qualitative analysis of interaction by affinity chromatography, we
used FP to quantify the interactions. For that we used E. coli PL kinase and several other PLPdependent enzymes, including, E. coli L-threonine aldolase (eL-TA), E. coli aspartate
aminotransferase (eAAT), E. coli serine hydroxymethyltransferase (eSHMT), rabbit cytosolic
serine hydroxymethyltransferase (rcSHMT) and glycogen phosphorylase b (GlyPb) from rabbit
muscle having molecular weights of 140 kDa, 90 kDa, 90.5 kDa, 220 kDa and 92 kDa
respectively. All of these enzymes belong to fold-type I, except GlyPb which belongs to foldtype V of B6 enzymes. The activity of PL kinase was not affected by the

tagging. The

interactions of PL kinase with eSHMT, eL-TA, eAAT, rcSHMT and GlyPb were analyzed and
the results are shown in Figure 25;
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Figure 25: Fluorescence polarization titration; Change in fluorescence polarization intensity
of FMI-PLK upon addition of increasing concentration of eSHMT (orange), eTA (light blue),
eAAT (purple), rcSHMT (red) and Gly Pb (green) in 50 mM sodium HEPES, pH 7.55 containing
150 mM KCl and 0.01% Triton. Controls LDH ( ) and lysozyme (+) were also run

A simple 1:1 model provided the best fit to the interactions, resulting in the Kd values that
range from 0.4-50 μM, as noted in Table 5. Similar experiments by Cheung et. al. with PL kinase
and pig alanine aminotransferase or glutamate decarboxylase resulted in Kd values 5-15 μM.35, 47
Interestingly, GlyPb binding was found to be the weakest. It may be due to the fact that it is the
most abundant B6 enzyme in the body and the weak binding may act as control mechanism in
order to prevent the GlyPb to out-compete all other apo B6 enzymes. In the experiments, we used
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lysozyme and lactate dehydrogenase (LDH, dimer;~140 kDa) as controls to show that non-B6
proteins did not have any significant binding to PL kinase. The variation in polarization values
between different PLP-dependent enzymes might be due to the difference in molecular weights
between them.
Table 5: Affinity data for interactions of PL kinase with eSHMT, rcSHMT, eAAT, eTA and
GlyPb
Enzyme

Affinity (Kd)

eSHMT

8 ± 1.2 μM

rcSHMT

8.4 ± 0.7 μM

eAAT

0.4 ± 0.01 μM

eTA

19 ± 2.8 μM

GlyPb

56 ± 8 μM

Fluorescence polarization data obtained for two different fold-types of PLP-dependent
enzymes indicates that the binding between PL kinase and different PLP-dependent enzymes is
specific. This data along with the binding data previously reported by Cheung et. al.47 provides a
very strong support to the argument of PLP channeling from PL kinase to PLP-dependent
enzymes.
3.5 Conclusion:
The data obtained from both affinity chromatography and fluorescence polarization
clearly indicates that PL kinase binds with PLP-dependent enzymes. This data along with results
of the PLP transfer experiments indicate that channeling of PLP from PL kinase to PLPdependent enzymes is a strong possibility.
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CHAPTER 4
DETERMINE THE EFFECT OF PL KINASE S261F MUTATION ON ENZYME
ACTIVITY AND STRUCTURE

4.1 Introduction: Several mutations on the genes coding for the B6 salvage enzymes, PL
kinase and PNP oxidase have been reported. In many of the cases, these mutations were found to
be deleterious to health, because they lead to decrease in the enzyme activity.18-20, 63-65 For PNP
oxidase, many mutations have been linked to the fatal disorder, Neonatal epileptic
encephalopathy.19, 20, 63 Decrease in co-factor (FMN) binding affinity is found to be the cause of
the decrease in activity in one of the mutant, R229W.19 Similarly defective PL kinase has been
reported in children suffering from autism.64 In this study, we determined the effect of a single
nucleotide polymorphism, causing S261F mutation, on human PL kinase activity. Single
nucleotide polymorphism, by definition, occurs in at-least 1% of the population.74 Hence, PL
kinase, if affected by the S261F mutation, can lead to several disorders in large population
carrying this SNP. This fact makes it essential to determine the effects of the mutation S261F on
PL kinase’s function and structure.
4.2 Materials: All culture media ingredients were purchased from Fischer Scientific
(Pittsburgh, PA) or American Bioanalytical (Natick, MA). Nickel nitriloaceticacid (NiNTA)
slurry was purchased from Qiagen (Valencia, CA). The QIAprep Spin Miniprep kit for plasmid
isolation was purchased from Qiagen (Valencia, CA). The Quickchange Site-directed
mutagenesis kit was purchased from Stratagene (La Jolla, CA).

All the substrates were

purchased from Sigma (St. Louis, MO). Centrifugal filter devices were obtained from Milipore
(Bedford, MA).
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4.3 Methods:
4.3.1 Site-directed mutagenesis: The recombinant plasmid containing gene pdxK,
coding for PL kinase, inserted in pET 28a(+) was isolated by Qiagen’s QIAprep Spin Miniprep
kit as per the protocol described by Qiagen. Polymerase chain reaction was carried out as per the
protocol given by Stratagene. The following primers were used to carry out polymerase chain
reaction;
Forward primer: CAC CAC GTT CCA TTT GTG CCA GAA GAG
Reverse primer: GTG GTG CAA GGT AAA CAC GGT CTT CTC
The PCR product was transformed to E. coli XL-1 blue super-competent cells and
transformants were grown on LB-agar media containing kanamycin (50 μg/mL) at 37°C. The
following day, one colony was picked up and grown in 10 mL LB media, containing kanamycin
(50 μg/mL), over night at 37°C. From this cell-culture, the plasmid, carrying the mutation, was
isolated as described above. This plasmid was sent to VCU’s DNA core facility for sequencing
to confirm the mutation.
4.3.2 Optimization of expression condition for hPL kinase mutant (S261F): The
mutant plasmid, after isolation from E. coli XL-1 blue supercompetent cells, was transformed to
E. coli Rosetta (DE3) pLys cells for expression. The transformants were grown on LB-agar
media containing kanamycin (50 μg/mL) and chloramphenicol (34 μg/mL), overnight at 37°C.
The following day, one colony was picked up and grown in 10 mL LB-kanamycinchloramphenicol media, overnight at 37°C and used to inoculate two separate 50 mL LBkanamycin-chloramphenicol media. The cells were grown at 37°C until the OD600nm reached to
0.8. The expression levels were analyzed at two different concentrations of βisopropylthiogalactopyranoside (IPTG), i.e. 50 μM and 0.5 mM. The cells, induced with 0.5 mM
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IPTG, were grown for additional 5 hours at 37°C; while the cells, induced with 50 μM IPTG,
were grown for 24 hours at 18°C. After the induction period, cells were harvested by
centrifugation and ruptured separately by high-pressure homogenization using Avestin cell
disruptor. For determination of expression levels, 1 mL of cell-lysate was taken from both the
mixtures and centrifuged. The supernatants containing soluble fraction of protein were collected.
The cell pellets, containing protein in insoluble fraction, were re-suspended using suitable buffer.
All of these fractions, containing protein in soluble, as well as, in insoluble forms were analyzed
by SDS-PAGE.
4.3.3 Large scale expression and purification of mutant human PL kinase (S261F):
The E. coli Rosetta (DE3) pLys cells containing the plasmid, carrying the mutation, were grown
overnight at 37°C with shaking in 200 mL LB-kanamycin-chloramphenicol media. It was used
to inoculate 4 L LB-kanamycin-chloramphenicol media the following morning. Cells were
grown until OD600nm reached to 0.8, induced with 50 μM β-isopropyl thiogalactopyranoside
(IPTG), grown for additional 24 hours at 18°C and then harvested by centrifugation. Cell pellets
were re-suspended in 150 mL cell-lysis buffer (50 mM NaH2PO4, pH 8 containing 300 mM NaCl
and 10 mM imidazole). After re-suspension, the cells were ruptured by high-pressure
homogenization using Avestin cell disruptor. Streptomycin sulfate was added to cell-lysate at
concentration of 10 g/L to remove excess nucleic acids, which was then centrifuged to remove
the precipitate and cell debris. The supernatant was decanted and loaded on NiNTA column, preequilibrated with lysis buffer. The column was washed thoroughly with lysis buffer until
OD280nm reached below 0.1, and further washed several times with the same buffer, containing
higher concentrations of imidazole (10-75 mM). The enzyme was eluted from the column with
50 mM monobasic sodium phosphate, pH 8.0, containing 300 mM NaCl, and 150 mM
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imidazole. Fractions containing protein of >95% purity, as judged by SDS-PAGE, were pooled
together and concentrated by precipitation with 60% ammonium sulfate. The protein pellets were
stored at -20°C for further usage.
4.3.4 Expression and purification of wild type PL kinase: The wild type PL kinase
was expressed and purified as described in chapter 2 under section 2.3.1
4.3.5 Activity analysis of purified PL kinase S261F: The activity analysis of purified
mutant enzyme was carried out as per the procedure described in chapter 2 under section 2.3.2
Activity analysis of wild type enzyme was also carried out in the same manner to compare its
activity with the mutant enzyme. Comparison was made at two different concentrations of both
enzymes, i.e. hPL kinase S261F and hPL kinase wild type.
4.3.6 Analysis of secondary structure: Secondary structural elements of wild-type and
mutant enzyme were analyzed by recording circular dichroism (CD) spectra in a 0.5 cm cell at
room temperature using Olis spectropolarimeter. The protein solutions were dialyzed against 20
mM potassium phosphate buffer, pH 7.2 and diluted to 0.1 mg/mL before analysis. All the
spectra were blanked against buffer and recorded in range of 180 nm to 250 nm. The spectra
were obtained in form of ellipticity vs. wave-length, which were normalized by converting
ellipticity to Molar ellipticity by using equation 5.

Where, Ɵ = molar ellipticity, Ɵ0 = observed ellipticity (in degrees), M = molecular weight, c =
concentration, l = path-length of the cell and
n = mean residual weight =
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4.3.7 Tertiary structure analysis: Both wild-type and mutant enzymes, dialyzed against
20 mM potassium phosphate buffer, pH 7.24, were analyzed by fluorescence spectroscopy. The
measurements were done in a 1 cm cell using Shimadzu RF-5301 spectrofluorometer. The
samples were excited at 295 nm and the emission-spectra were recorded between 300 to 400 nm,
after blanking the spectrofluorometer against buffer. The slit-width was adjusted at 7.5 mm and
all the measurements were done at room temperature.
4.3.8 Oligomerization state analysis: To check the oligomerization state, both mutant
and wild-type enzymes were analyzed by native-PAGE. About 10 μL of each enzyme were
mixed with 10 μL of native sample buffer and loaded on native gel. The gel was prepared
without denaturants (SDS). It was run at 15 volts for about 2 hours. The gel was stained and,
after destaining, analyzed for band positions of both the mutant and the wild-type enzyme.
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4.4 Results and Discussion:
4.4.1 Site-directed mutagenesis: The sequencing of isolated plasmid, carrying the
mutation, was performed at DNA core facility at VCU. It was done by using standard T7
promoter and T7 terminator primers. These primers were used for sequencing, as the vector
pET28a(+) contained the T7-promoter and terminator sequences. The obtained sequence data
was read in Applied Biosystem’s sequence viewer and it confirmed the mutation S261F.
4.4.2: Optimization of expression condition for hPL kinase S261F: The main goal of
expression condition optimization was to obtain the condition at which maximum amount of
protein can be expressed to carry out further studies. The expression levels were analyzed at two
different concentration of IPTG, which serves to induce protein production by bacteria. In one
condition, IPTG was added to a concentration of 0.5 mM and cells were grown at 37°C, while in
second condition, IPTG was added to a concentration of 50 μM and cells were grown at 18°C.
The first condition is for fast induction, while the second is for slow induction. Slow induction,
in some cases, may help in getting more soluble yields of protein due to more available folding
opportunities during a slower process. In our case, both the conditions were analyzed before
large-scale production. Figure 26 shows the result of analysis;
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Figure 26: SDS-PAGE analysis for expression condition optimization of hPL kinase S261F;
lane 1 corresponds to protein-marker, lane 2 and 3 correspond to protein in insoluble fractions
for protein expressed at 37°C and 18°C respectively while lane 4 and 5 corresponds to the
soluble fractions for 37°C and 18°C , respectively

As shown in Figure 26, the level of expression was slightly greater at 18°C, when low
IPTG concentration was used. Therefore, the condition of low temperature with low IPTG
concentration was used for large-scale protein-expression.
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4.4.3 Large-scale expression and purification of human PL kinase S261F: The
protein contained 6x-His tag at its N-terminal. Hence, purification, after cell-lysis, was
performed by loading the cell-lysate on NiNTA column. Figure 27 shows the purification profile
for hPL kinase S261F, and shows the enzyme purified to homogeneity, which was suitable for all
further studies.

Figure 27:Purification profile of hPL kinase S261F; SDS-PAGE analysis of fractions eluted
from NiNTA column when the column was washed with 50 mM NaH2PO4 containing 300 mM
NaCl and 150 mM Imidazole
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4.4.4 Activity analysis: The enzymatic activity of the mutant and wild-type were studied
and compared. Table 6 shows the result of that analysis;

Table 6: Activity comparison of hPL kinase S261F and wild-type hPL kinase at two different
concentrations of enzymes
Rate (min-1)
Enzyme concentration (mg/mL)
Wild-type

Mutant

0.1

0.0275 ± 0.006

0.0235 ± 0.01

0.2

0.0492 ± 0.015 0.0524 ± 0.012

This analysis indicated that both the proteins were equally active and mutation had no
effect on activity of protein. On the basis of this study, in-depth kinetic analysis was not pursued.
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4.4.5 Secondary structure analysis: Circular Dichroism is a sensitive technique for
characterization of protein structure. It can readily detect any change in protein structure.83
Figure 28 shows the spectra for both proteins;
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Figure 28: Secondary structure comparison; CD spectra of both hPL kinase wild-type
(blue) and hPL kinase S261F (red)

The Far UV-CD spectra for both, wild-type and mutant enzymes were found to resemble
each other, which suggest that the proteins have similar secondary structures; thus the mutation
was not found to have any obvious effect on the secondary structure.
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4.4.6 Tertiary structure analysis: Tertiary structures of the mutant, with the wild type
as a control, were analyzed using fluorescence spectroscopy, by exciting the proteins at 295 nm
and recording the emission spectra between 300-400 nm. This analysis employs the property of
tryptophan residues, which have excitation maximum at 295 nm. Depending upon their local
environment, characteristic emission spectrum with maximum between 308-355 nm is obtained.
Any change in structure of protein and hence environments of tryptophan residues can change
the spectrum also.76 Therefore, the comparison of spectra of wild-type and mutant hPL kinase
can yield valuable information regarding the structural change, if any.
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Figure 29: Tertiary structure comparison; Fluorescence emission spectra for hPL kinase wildtype (red) and hPL kinase S261F (blue)
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Figure 29 shows the fluorescence spectra for both the hPL kinase wild-type and hPL
kinase S261F, which indicates a slight decrease in the emission maximum as compared to wildtype enzyme, but no shift of the maximum was noticed. The decrease in emission maximum
could be due to a slight variation in protein concentrations because of difference in purity of both
the enzymes. The result however shows that the tertiary structures of both the proteins are almost
similar. The S261F mutation is probably not altering the structure and hence the function of hPL
kinase.
4.4.7 Oligomerization state analysis: The oligomerization state of the mutant with the
wild type as a control was analyzed using Polyacrylamide gel electrophoresis (PAGE) under
native conditions. The native PAGE separates the proteins depending on their molecular weights.
Figure 30 shows native-PAGE analysis for both hPL kinase wild-type and hPL kinase S261F;

Figure 30: Oligomerization state comparison; native PAGE analysis of hPL kinase
wild-type and hPL kinase S261F
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Figure 30 clearly indicates that hPL kinase S261F is in identical oligomerization state as
the wild-type enzyme and mutation is probably not affecting the quaternary structure as well.
4.5 Conclusion: The effect of a Single Nucleotide Polymorphism in gene pdxK, coding
for PL kinase S261F was analyzed. The mutant protein was successfully expressed and purified
to homogeneity. This mutant was compared with the wild-type enzyme for its catalytic activity,
as well as, secondary, tertiary and quaternary structures. In all aspects, it was found to be
identical with wild-type enzyme. The results show that this SNP (S261F) in pdxK might not have
any pathological implications.
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CHAPTER 5
DETERMINE THE EFFECT OF GINKGOTOXIN ON PL KINASE ACTIVITY AND
STRUCTURE

5.1 Introduction: For a very long time Ginkgo biloba has been considered as an
important therapeutic agent. It is even considered sacred in some parts of the world because of its
presumed therapeutic property. In mainland China and Japan, as well as several parts of the
world, preparations from Ginkgo biloba are used to treat conditions such as, insufficiency of
blood-flow, cerebral insufficiency, memory deficit, lack of concentration, depression, dizziness,
tinnitus, vertigo and headaches, bronchial asthma, irritable bladder, cough and even alcohol
abuse.28 Several clinical trials have also been reported for various preparations of G. biloba, but
these studies have always resulted in controversial outcomes.28 Several reports for detailed
analysis of G. biloba’s constituents have been published and they have identified an array of
different constituents, including ginkgotoxin, also known as 4’-O-methylpyridoxine .29, 30 Apart
from G. biloba, Ginkgotoxin is also found to be present in Albizzia species.66 Ginkgotoxin, as the
name suggests, is a potent neurotoxin. Toxicity occurs due to over-dose of any medicinal
preparation from G. biloba or by ingestion of seeds, which are used in diet in Japan, as well as in
China.30,
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Toxicities associated with ginkgotoxin are characterized by symptoms such as

seizures, tonic/clonic convulsions, vomiting and impaired consciousness, which disappear with
administration of PLP.27, 29 This led to the suggestion that ginkgotoxin may have inhibitory effect
on PL kinase and/or PNP oxidase activities. Several studies have confirmed ginkgotoxin’s
inhibitory activity against the kinase, but not the oxidase.27, 28, 77 However, it has been suggested
that the phosphorylated form of ginkgotoxin could inhibit the oxidase activity. This means that in
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vivo phosphorylation of ginkgotoxin by the kinase may act on the oxidase to inhibit its activity.
We have carried out in-depth kinetic analysis for ginkgotoxin inhibition of PL kinase and also
used structural studies to understand the molecular basis of the inhibition. .
5.2 Materials:
The ginkgotoxin used in this study was synthesized by Dr. Danso-Danquah Richmond at
the Institute for Structural Biology and Drug Discovery, VCU.
5.3 Methods:
5.3.1 Expression and purification of human PL kinase: Human PL kinase was
expressed and purified as described previously in chapter 2 under section 2.3.1. The purified
protein fractions after the NiNTA column were pooled together. Ammonium sulfate was added
to 60% saturation to precipitate the protein. The protein pellet after ammonium sulfate was
stored at -20°C for further use.
5.3.2 Determination of kinetic parameters for inhibition of PL kinase by
ginkgotoxin: The protein was dialyzed against 20 mM sodium BES buffer, pH 7. All the assays
were done in a 1 cm thermo-stated cuvette using Agilent 8451 spectrophotometer. The assay for
pyridoxal kinase activity was done as described previously in chapter 2 under section 2.3.2. The
initial velocity data were recorded under the kinetic mode. For determination of kinetic
parameters for inhibition, it was assumed that ginkgotoxin, due to structural similarity with PL,
binds at the PL site. To confirm that and to determine the Ki for inhibition, three different
concentrations (25 μM, 50 μM and 75 μM) of the drug ginkgotoxin were used and PL kinase was
analyzed for activity at variable concentrations of PL (20-100 μM). MgATP was used at
concentration of 1 mM. The initial velocity data were recorded in duplicate. The reciprocal rate
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data were plotted against reciprocal of PL concentrations to obtain Lineweaver-Burk plot. The
type of inhibition and kinetic parameter for the inhibition were determined from the plot.
5.3.3 Crystallization of PL kinase along with ginkgotoxin: PL kinase was first
dialyzed against 20 mM sodium BES buffer, pH 7 containing 200 mM NaCl and 5 mM βmercaptoethanol. The obtained protein solution was then concentrated to 25 mg/mL by using
Centricon YM-10 centrifugal filter device. The concentrated protein solution was finally
dialyzed against 20 mM sodium BES buffer, pH 7 containing 150 mM NaCl and 5 mM βmercaptoethanol.
Wild-type PL kinase has previously been crystallized using 100 mM Tris-HCl, pH 8.0,
and 52% 2-methyl-2,4-pentandiol (MPD) and 2.5 mM MgSO4. Therefore, all the cocrystallization attempts of PL kinase (700 μM) with ginkgotoxin (2 mM) and MgATP (1 mM)
were focused around this condition. MPD concentration was varied between 45-60%. Hangingdrop method was used for the crystallization. X-ray quality crystals were obtained at the
condition with 48% MPD.
5.3.4 Data collection, integration and scaling: The crystal was cryo-protected in
mother-liquor solution containing 1 mM MgATP and 2 mM ginkgotoxin and diffraction data
collected at 100K using a Molecular Structure Corporation (MSC) X-Stream Cryogenic Crystal
Cooler, a Rigaku IV ++ image plate detector, and a Rigaku MicroMax-007 X-Ray source
(copper) fitted with MSC Varimax Confocal optics operating at 40 kV and 20 mA. Detector
distance was set at 135 mm and exposure time was set at 2 minutes for each of the three frames,
for which data was collected to assign unit cell parameters. After determining cell parameters, a
total of 240 oscillation frames were collected, each at six minutes of exposure time. The data was
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collected from φ 45° to 165° with 0.5° variations within each frame. Cell parameter determination
and integration and scaling of data was done by d*trek provided in CrystalClear program
package by Rigaku America Co. Integration of data was done by setting the resolution from 30 Å
to 2.05 Å.
5.3.5 Structure determination: The diffraction intensity data was first converted to
structure factor using the CCP4 suite of programs.82 The isomorphous structure of hPL kinase
D235A mutant (pdb id 2FHX) was used as a starting model for structure determination. The
bound MgATP, MPDs, waters and sulfates were omitted for refinements. All the refinements
were done using CNS (Crystallographic and NMR systems) program.78 Rigid body refinement,
conjugate gradient minimization, simulated annealing and B-factor refinements were performed.
This led to identification of ginkgotoxin density at the PL site of both the subunits. MgATP
density was also identified at both subunit active sites. The graphic programs, TOM79 and COOT
(Crystallographic object-oriented tool-kit)80 were used for manual model adjustment as well as
including the ginkgotoxin, MgATP, water, sulfate, MPD to the model. Refinements with
intermittent model rebuilding have resulted in the current Rfree/Rwork of 28.3/25.4. Further
refinement is ongoing. The data collection statistics and refinement parameters are shown in
Table 7.
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Table 7: Data collection statistics and refinement parameters for the structure of human PL
kinase bound with ginkgotoxin
Data collection statistics
Space group

I222

Unit cell a, b, c (Å)

92.75, 115.22, 169.55

Resolution range (Å)

28.81-2.10 (2.18-2.10)

Total number of reflections

186720

Number of unique reflections

49278

Average redundancy

3.79 (3.84)

% completeness

92.5 (92.3)

Output <I/ Σ(I)>

16.5 (8.3)

Rmergea

0.075 (0.288)

Refinement Statistics
Rfree (%)b

28.3

Rwork (%)c

25.4

Average B (Å2)/No. of non-H atoms
Protein

40.4

Water

33

MPD

72.8

Anion

97.1

Cation

39.6

ATP

33.3

Numbers in parentheses refer to the outer (highest) resolution shell
a
Rmerge = Σ|I -〈I〉 |/Σ(I), where I is the observed intensity and 〈I〉 is the weighted mean of the
reflection intensity
b
Rwork = Σ||Fo| -Fc|| / Σ|Fo|, where Fo and Fc are the observed and calculated structure factor
amplitudes, respectively
d
Rfree is the crystallographic Rwork calculated with 5 % of the data that were excluded from
the structure refinement
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5.4 Results and Discussion:
5.4.1 Determination of kinetic parameter for hPL kinase inhibition: Ginkgotoxin was
tested for its inhibitory effects on hPL kinase. It was found to potently inhibit enzyme’s activity
with Ki of 18 μM. The Lineweaver-Burk plot also suggests the inhibitory effect of ginkgotoxin to
be competitive with the substrate PL.
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Figure 31: Lineweaver-Burk plot for characterization of Ginkgotoxin inhibition on hPL
kinase
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The study shows that Ginkgotoxin competitively inhibits PL binding, resulting in
decrease in the metabolism of PL to PLP. Deficiency of PLP could potentially lead to disruption
of the functions of several PLP-dependent enzyme activities causing neurotoxic effect. The
competitive inhibition also suggests that ginkgotoxin is binding at the PL site of the enzyme.
5.4.2 Structure of ginkgotoxin bound at PL kinase: Based on the kinetic studies that
suggested ginkgotoxin may be binding at the PL binding site, we undertook structural studies to
confirm this and also to explain on atomic level how this compound inhibits the kinase. Cocrystals of PL kinase-ginkgotoxin were obtained with a minor modification of a previously
reported crystallization condition for the wild type enzyme.6 The structure was determined to a
resolution of 2.1 Å. The current model contains 2 ginkgotoxin molecules, 2 ATP molecules, 2
each of Na+ and Mg2+, 125 water, 6 sulfate and 6 MPD molecules. Both active sites have bound
ginkgotoxin that closely superimpose on the substrate, PL. Figure 32 shows the dimeric PL
kinase structure with bound MgATP and ginkgotoxin. The detailed PL kinase structure as well
as the active site structure of PL kinase has previously been described.6
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Figure 32: Dimeric structure of human PL kinase bound with ginkgotoxin and ATP; shown
as spheres in yellow and red respectively. Monomer A and B are shown in green and blue
respectively.

Figure 33: Superposition of human PL kinase (unliganded) and human PL kinase
(inhibitor- bound); shown in red and cyan respectively
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Figure 33 shows superposition of human PL kinase (unliganded) and human PL kinase
with ginkgotoxin. The rmsd for the superposition was 0.4 Å, and shows that binding of
ginkgotoxin to PL kinase does not have a significant effect on the overall conformation of PL
kinase dimeric structure.
Each monomer of PL kinase has a unique active site that binds ATP, Mg2+ and Na+
molecules, as well as a ginkgotoxin. The mode of ginkgotoxin binding is shown in Figure 34,
which is similar to those described for previously published binary complexes of PL kinase with
bound PL.5

Figure 34: Binding of ginkgotoxin at the active-site of PL kinase
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Figure 35: Superposition of human PL kinase (unliganded), sheep brain PL kinase (PL
bound) and human PL kinase (inhibitor-bound) shown in red, yellow and cyan respectively

Figure 35 also shows superposition of the active-sites of human PL kinase (unliganded),
human PL kinase- ginkgotoxin complex, and sheep brain PL kinase-PL complex. The structural
comparison shows that ginkgotoxin binds in a similar fashion as pyridoxal, without any gross
change in the active site structure. As expected, the interactions associated with PL binding are
conserved with ginkgotoxin binding. These include a hydrogen-bond interaction between O3 of
ginkgotoxin and the main-chain nitrogen of Thr47; between N1 of ginkgotoxin and the –OH
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group of Ser12; between the hydroxyl of the 5’–CH2OH and the carboxylate of Asp235.
Theophylline and roscovitine, known inhibitors of PL kinase, are also known to inhibit PL kinase
by binding to PL site of PL kinase, interacting with the same residues described above. 26 There
are two unique interactions, that are absent in the PL binding complex, which may serve to
explain the high affinity of ginkgotoxin to PL kinase. The 4’-O-methyl substituent of
ginkgotoxin, which is absent in PL, is found to be located between and forming hydrophobic
interactions with the protein residues Tyr127 and Val231. Also, 5’–CH2OH of ginkgotoxin is
involved in hydrogen-bond interaction with a nearby water molecule, which is held in position
by hydrogen-bond interactions with the nearby Gln12 and Asp235. Although this water molecule
is present in the unliganded PL kinase, it may possibly be playing structural role in ginkgotoxin
binding.
5.4 Conclusion: Detailed kinetic analysis of ginkgotoxin’s inhibition of PL kinase
activity was carried out. It was found to inhibit PL kinase with a Ki of 18 μM, which is lower
than the reported Km of 30 μM for PL. From the kinetic analysis it was found to be a competitive
inhibitor of the substrate PL. The X-ray crystallographic structure of PL kinase-ginkgotoxin
complex shows that ginkgotoxin bind at the PL site of each subunit without any gross change in
protein conformation, but with additional protein interactions. This data gave an insight into the
mechanism of ginkgotoxin inhibitory activity. The structural studies also suggest that the 5’–
CH2OH could easily be phsophorylated by the enzyme which can act on the oxidase to inhibits
activity.
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